GDC-0449 and RO4929097 are two new investigational drugs currently being assessed for the treatment of sarcoma. The purpose of the phase IB portion of this study is to find the optimal doses of these drugs to use in patients with metastatic and recurrent sarcoma. The purpose of the phase II portion is to see how effective the drugs are against sarcoma. Both drugs are pills that are taken orally (by mouth).
“Hedgehog” and “Notch” are two groups of proteins that cause cancer cells to grow continuously. GDC-0449 blocks the activity of the Hedgehog pathway, while RO4929097 blocks the activity of the Notch pathway. Laboratory studies have shown that a Hedgehog inhibitor and a Notch inhibitor are more effective when they are used together than separately.